Due to health issues, this site is no longer maintained and will be shut down shortly. |
Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
$6.04 +0.47 (8.44%)
As of 03/24/2023 16:30:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.